Zydus Lifesciences gets EIR report with Nill observations from USFDA

05 Nov 2025 Evaluate

Zydus Lifesciences has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for an inspection at the group’s manufacturing plant located SEZ - II, Ahmedabad, from August 11, 2025 to August 14, 2025. The inspection was a Pre-Approval Inspection (PAI). The USFDA has concluded this inspection as closed. The inspection concluded with NIL observations. The EIR has classified the facility as No Action Indicated (NAI).

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.

Zydus Lifesciences Share Price

931.45 -3.75 (-0.40%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×